Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia

NCT05636514 is registered in ClinicalTrials.gov with Clinical Hub for Interventional Research (CHOIR) as lead sponsor.

NCT NCT05636514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05636514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia
Lead sponsor
Clinical Hub for Interventional Research (CHOIR)
Phase
Phase 1
Overall status
Recruiting
Start date
December 14, 2022
Completion date
December 30, 2027
Enrollment
12 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndromes